Cargando…

Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases

Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of hemoglobin (Hb) from glutamate to valine. This singular mutation results...

Descripción completa

Detalles Bibliográficos
Autores principales: Alabi, Oladeji John, Adegboyega, Fikayo Noah, Olawoyin, Dolapo Samuel, Babatunde, Oluwakemi Arinola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167986/
https://www.ncbi.nlm.nih.gov/pubmed/35677416
http://dx.doi.org/10.1016/j.heliyon.2022.e09630
_version_ 1784720899241410560
author Alabi, Oladeji John
Adegboyega, Fikayo Noah
Olawoyin, Dolapo Samuel
Babatunde, Oluwakemi Arinola
author_facet Alabi, Oladeji John
Adegboyega, Fikayo Noah
Olawoyin, Dolapo Samuel
Babatunde, Oluwakemi Arinola
author_sort Alabi, Oladeji John
collection PubMed
description Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of hemoglobin (Hb) from glutamate to valine. This singular mutation results to disorderliness in red blood cells (RBCs) with advent of changes in RBC morphology and other pathological conditions. In the 1980s, intermittent red blood cell transfusions, opioids, and penicillin prophylaxis were the only available therapy for SCA and were commonly reserved for acute, life threatening complications. So far, the US Food and Drug Administration (FDA) has granted a total of four drugs approval for the prophylaxis and treatment of the clinical complications of SCD. Due to limitations (adherence, safety, adverse effects) of existing therapies in the prophylaxis and treatment of SCD complications in Nigerian children and their inaccessibility to approved drugs, the present study discusses the therapeutic effects of readily available functional food as one of the therapies or an adjunct therapy to tackle the sickle cell crisis in Nigerian Children.
format Online
Article
Text
id pubmed-9167986
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91679862022-06-07 Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases Alabi, Oladeji John Adegboyega, Fikayo Noah Olawoyin, Dolapo Samuel Babatunde, Oluwakemi Arinola Heliyon Review Article Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of hemoglobin (Hb) from glutamate to valine. This singular mutation results to disorderliness in red blood cells (RBCs) with advent of changes in RBC morphology and other pathological conditions. In the 1980s, intermittent red blood cell transfusions, opioids, and penicillin prophylaxis were the only available therapy for SCA and were commonly reserved for acute, life threatening complications. So far, the US Food and Drug Administration (FDA) has granted a total of four drugs approval for the prophylaxis and treatment of the clinical complications of SCD. Due to limitations (adherence, safety, adverse effects) of existing therapies in the prophylaxis and treatment of SCD complications in Nigerian children and their inaccessibility to approved drugs, the present study discusses the therapeutic effects of readily available functional food as one of the therapies or an adjunct therapy to tackle the sickle cell crisis in Nigerian Children. Elsevier 2022-06-02 /pmc/articles/PMC9167986/ /pubmed/35677416 http://dx.doi.org/10.1016/j.heliyon.2022.e09630 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Alabi, Oladeji John
Adegboyega, Fikayo Noah
Olawoyin, Dolapo Samuel
Babatunde, Oluwakemi Arinola
Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases
title Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases
title_full Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases
title_fullStr Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases
title_full_unstemmed Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases
title_short Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases
title_sort functional foods: promising therapeutics for nigerian children with sickle cell diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167986/
https://www.ncbi.nlm.nih.gov/pubmed/35677416
http://dx.doi.org/10.1016/j.heliyon.2022.e09630
work_keys_str_mv AT alabioladejijohn functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases
AT adegboyegafikayonoah functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases
AT olawoyindolaposamuel functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases
AT babatundeoluwakemiarinola functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases